Regulus Therapeutics Inc.
RGLS
$7.84
-$0.03-0.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -47.52M | -46.36M | -41.63M | -35.39M | -31.37M |
| Total Depreciation and Amortization | 351.00K | 347.00K | 336.00K | 302.00K | 260.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.12M | 6.22M | 5.16M | 4.28M | 3.55M |
| Change in Net Operating Assets | -3.49M | -1.88M | 183.00K | -1.97M | 164.00K |
| Cash from Operations | -43.54M | -41.67M | -35.95M | -32.78M | -27.40M |
| Capital Expenditure | -111.00K | -340.00K | -411.00K | -924.00K | -841.00K |
| Sale of Property, Plant, and Equipment | -- | -- | 3.00K | 3.00K | 3.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 64.17M | -35.64M | -54.64M | -78.21M | -78.21M |
| Cash from Investing | 64.06M | -35.98M | -55.05M | -79.14M | -79.05M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -551.00K | -1.38M | -2.20M | -3.03M | -3.30M |
| Issuance of Common Stock | 115.00K | 94.00M | 93.94M | 95.04M | 109.08M |
| Repurchase of Common Stock | -74.00K | -74.00K | -121.00K | -121.00K | -47.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -133.00K | -133.00K | -69.00K | -119.00K | -- |
| Cash from Financing | -643.00K | 92.42M | 91.54M | 91.78M | 105.73M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 19.87M | 14.76M | 540.00K | -20.14M | -722.00K |